Advancements in AI-based CT-FFR Analysis with DEEPVESSEL FFR: A Comprehensive Research Overview
Keya Medical’s AI CT-FFR Analysis: focus on its research and publications journey since DEEPVESSEL FFR FDA-clearance.
Keya Medical Presents FDA-cleared CT FFR product at SCCT Global 2024 | Budapest
Visit Keya Medical’s booth at SCCT Global 2024 in Budapest, January 16-19.
Enhancing Cardiovascular Care: The Story of DEEPVESSEL FFR by Keya Medical
Keya Medical’s DEEPVESSEL FFR offers a non-invasive, accurate, and efficient solution for assessing coronary artery function. The product’s journey from inception to global clearances reflects a commitment to advancing medical technology and improving patient outcomes...
Keya Medical Covers Technology Advancements and AI Integration at SCCT 2023: A Look at Exceptional Collaborations.
In the dynamic landscape of medical innovation, SCCT 2023 served as an exceptional platform for exchanging cutting-edge insights and breakthroughs in cardiovascular technology.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Recent Comments